ARTICLE | Clinical News
MRX-I: Phase II data
September 7, 2015 7:00 AM UTC
Top-line data from a double-blind, Chinese Phase II trial in 178 evaluable patients with cSSTIs showed that twice-daily 600 and 800 mg oral MRX-I for up to 14 days each met the primary endpoint of non...